In last trading session, Edgewise Therapeutics Inc (NASDAQ:EWTX) saw 16.11 million shares changing hands with its beta currently measuring 0.33. Company’s recent per share price level of $15.52 trading at -$4.61 or -22.90% at ring of the bell on the day assigns it a market valuation of $1.48B. That closing price of EWTX’s stock is at a discount of -145.62% from its 52-week high price of $38.12 and is indicating a premium of 3.99% from its 52-week low price of $14.90. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.85 million shares which gives us an average trading volume of 1.18 million if we extend that period to 3-months.
For Edgewise Therapeutics Inc (EWTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.44. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.42 in the current quarter.
Edgewise Therapeutics Inc (NASDAQ:EWTX) trade information
Upright in the red during last session for losing -22.90%, in the last five days EWTX remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $15.52 price level, adding 38.8% to its value on the day. Edgewise Therapeutics Inc’s shares saw a change of -41.87% in year-to-date performance and have moved -30.28% in past 5-day. Edgewise Therapeutics Inc (NASDAQ:EWTX) showed a performance of -36.65% in past 30-days. Number of shares sold short was 9.09 million shares which calculate 6.69 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 50 to the stock, which implies a rise of 68.96% to its current value. Analysts have been projecting 50 as a low price target for the stock while placing it at a high target of 51. It follows that stock’s current price would drop -222.16% in reaching the projected high whereas dropping to the targeted low would mean a loss of -222.16% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -49.00% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -29.59% while estimates for its earnings growth in next 5 years are of -12.71%.
Edgewise Therapeutics Inc (NASDAQ:EWTX)’s Major holders
Insiders are in possession of 0.46% of company’s total shares while institution are holding 111.03 percent of that, with stock having share float percentage of 111.55%. Investors also watch the number of corporate investors in a company very closely, which is 111.03% institutions for Edgewise Therapeutics Inc that are currently holding shares of the company. ORBIMED ADVISORS LLC is the top institutional holder at EWTX for having 15.02 million shares of worth $270.54 million. And as of 2024-06-30, it was holding 16.0634 of the company’s outstanding shares.
The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 8.91 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.5269 of outstanding shares, having a total worth of $160.45 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.52 shares of worth $39.09 million or 2.65% of the total outstanding shares. The later fund manager was in possession of 1.87 shares on Feb 28, 2025 , making its stake of worth around $29.09 million in the company or a holder of 1.97% of company’s stock.
